Last reviewed · How we verify
Survanta
At a glance
| Generic name | Survanta |
|---|---|
| Also known as | Survanta (Ross Laboratories), Beractant |
| Sponsor | NICHD Neonatal Research Network |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | discontinued |
Approved indications
- Respiratory distress syndrome in the newborn
Common side effects
Key clinical trials
- Evaluation of the Efficacy of Different Surfactant Preparations in Preterm Infants by Lung Ultrasound (NA)
- A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome (NA)
- Feasibility Study of A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants (Phase 2)
- Early Surfactant Followed by Nasal CPAP to Reduce the Use of Mechanical Ventilation Without Additional Morbidity in Infants 1250- 2000 Grams With RDS (Phase 3)
- Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen (Phase 4)
- Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome (Phase 2)
- Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial (Phase 2)
- A Prospective Pilot Controlled Trial Comparing the Intrapulmonary Distribution of Exogenous Surfactant Between (LISA) and Conventional Endotracheal Intubation in Preterm Neonates With RDS Using Lung U (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |